SAN DIEGO, Oct. 31, 2018 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet…Original Article
Heron Announces FDA Submission of HTX-011 NDA for Postoperative Pain Management
